Intellia faces backlash after halting drug work and layoffs, despite strategic decisions to focus on best ideas. Click here to find out why NTLA is a Sell.

周一，Oppenheimer调整了对Intellia Therapeutics (NASDAQ:NTLA)股票的展望，将公司的目标价从之前的60.00美元下调至40.00美元。尽管目标价下调，但该公司仍维持对这家生物技术公司股票的"优于大市"评级。这一决定是在Intellia Therapeutics宣布战略调整和裁员以延长财务周期后做出的。

智通财经APP获悉，美国基因编辑公司Intellia ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

（马萨诸塞10日讯）美国基因编辑公司Intellia ...

周五，BMO Capital Markets调整了对Intellia Therapeutics股票的展望，将目标价从之前的70美元下调至50美元，同时维持"跑赢大市"评级。此次调整是在Intellia Therapeutics分享了其展望2025年的战略计划之后做出的，该计划包括专注于执行ATTR和HAE的III期试验，目标是在2027年前获得HAE的批准。

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on ...

智通财经APP获悉，美国基因编辑公司Intellia Therapeutics(NTLA.US)表示，计划将其资源集中在开发候选药物NTLA-2002和nex-z上，并停止NTLA-3001的开发，这 ...